Perspective
Jun. 26, 2013
Myriad conflicts with real world molecular biology
A reasonable application of the human intervention standard would have resulted in a more balanced result. By Michael H. Anderson, Daniel M. Cislo and Mark D. Nielsen
In a unanimous opinion, on June 13, the Supreme Court drew a sharp line between isolated DNA (not patentable subject matter) and cDNA (patentable subject matter). See Association for Molecular Pathology v. Myriad Genetics, 2013 DJDAR 7484 (2013). In so doing, the court affirmed in part and reversed in part the Federal Circuit's decision regarding the subject matter eligibility of Myriad's ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In